Wilbanks Smith & Thomas Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,101	Closed	-$333K	–	501
2022 Q3	$333K	Buy	5,101 +633	+14%	+$45.9K	0.01%	349
2022 Q2	$272K	Hold	4,468	–	–	0.01%	395
2022 Q1	$235K	Buy	4,468 +1,638	+58%	+$103K	0.01%	445
2021 Q4	$214K	Sell	2,830 -66,767	-96%	-$5.83M	0.01%	481
2021 Q3	$7.79M	Buy	69,597 +67,125	+2,715%	+$8.43M	0.31%	75
2021 Q2	$400K	Buy	2,472 +472	+24%	+$57.4K	0.02%	344
2021 Q1	$244K	Hold	2,000	–	–	0.01%	416
2020 Q4	$306K	Buy	+2,000	New	+$236K	0.01%	331

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CRSP Position: Q4 2022 in Review

Wilbanks Smith & Thomas Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 5,101 shares — an estimated $333K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CRSP in Q4 2020 and held it in 8 quarters. The position peaked at $7.79M in Q3 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Wilbanks Smith & Thomas Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 5,101 CRISPR Therapeutics shares in Q4 2022, an estimated $333K.
Wilbanks Smith & Thomas Asset Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 8 quarters.
Wilbanks Smith & Thomas Asset Management's CRISPR Therapeutics position peaked at $7.79M in Q3 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.